Log in

Relevant bibliographies by topics / Asthma – Treatment / Journal articles

Journal articles on the topic 'Asthma – Treatment'

To see the other types of publications on this topic, follow the link: Asthma – Treatment.

Author: Grafiati

Published: 4 June 2021

Last updated: 20 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Asthma – Treatment.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Syabbalo, Nightingale. "Severe Neutrophilic Asthma: Pathogenesis and Treatment." Journal of Thoracic Disease and Cardiothoracic Surgery 3, no. 1 (January 15, 2022): 01–13. http://dx.doi.org/10.31579/2693-2156/030.

Full text

Abstract:

Asthma is a common chronic airway disease affecting about 358 million people worldwide, and an estimated 7 million children globally. Approximately 10% of patients with asthma have severe refractory disease, which is difficult to control on high doses of inhaled corticosteroids and other modifiers. Among these, are patients with severe neutrophilic asthma. Neutrophilic asthma is a severe phenotype of asthma, characterized by frequent exacerbations, persistent airway obstruction, and poor lung function. Immunopathologically, it is characterized by the presence of high levels of neutrophils in the airways and lungs. Interleukin-17 produced by Th17 cells, plays a key role in the pathogenesis of neutrophilic asthma by expressing the secretion of chemoattractant cytokines and chemokines for the recruitment, and activation of neutrophils. Interleukin-8 is a powerful chemoattractant and activator of neutrophils. Activated neutrophils produce an oxidative burst, releasing multiple reactive oxygen species, proteinases, cytokines, which cause airway epithelial cell injury, inflammation, airway hyperresponsiveness, and remodeling. Furthermore, exasperated neutrophils due to viral, bacterial or fungal infections, and chemical irritants can release extracellular nucleic acids (DNA), designated as NETs (neutrophil extracellular traps), which are more toxic to the airway epithelial cells, and orchestrate airway inflammation, and release alarmin cytokines. Dysregulated NETs formation is associated with severe asthma. Most patients with neutrophilic asthma are unresponsive to the standard of care, including high dose inhaled corticosteroids, and to targeted biologics, such as mepolizumab, and dupilumab, which are very effective in treating eosinophilic asthma. There is unmet need to explore for novel biologics for the treatment of neutrophilic asthma, and in refining therapies, such as bronchial thermoplasty.

APA, Harvard, Vancouver, ISO, and other styles

2

Syabbalo, Nightingale. "Aerosol Biologics for the Treatment of Eosinophilic Asthma." Journal of Thoracic Disease and Cardiothoracic Surgery 3, no. 1 (January 15, 2022): 01–05. http://dx.doi.org/10.31579/2693-2156/035.

Full text

Abstract:

Asthma is a heterogeneous chronic airway disease comprising of distinct phenotypes characterized by different immunopathophysiologic pathways, clinical features, disease severity, and response to treatment. The phenotypes of asthma include eosinophilic, neutrophilic, mixed cellularity, and paucigranulocytic asthma. Eosinophilic asthma is principally a T helper type 2 (Th2)-mediated airway disease. However, several other immune and structural cells secrete the cytokines implicated in the pathogenesis of eosinophilic asthma. Innate type 2 lymphoid cells, mast cells, basophils, and eosinophils secrete Th2 cytokines, such as interleukin-4 (IL-4), IL-13, and IL-5. Additionally, airway epithelial cells produce alarmin cytokines, including IL-25, IL-33, and thymic stromal lymphopoietin (TSLP). Alarmins are the key initiators of allergic inflammation at the sentinel mucosal surfaces. Innovative biotherapeutic research has led to the discovery of monoclonal antibodies which target and inhibit the immunopathological effects of the cytokines involved in the pathogenesis of eosinophilic asthma. Parenteral biologics targeting the inciting interleukins, include mepolizumab and reslizumab (anti-IL-5), benralizumab (anti-IL-5Rα), dupilumab (anti-4Rα), and tezelizumab (anti-TSLP). They have been shown to significantly reduce annualized exacerbation rates, improve asthma control, lung function, and quality of life. Currently, there are no pulmonary delivered aerosol biologics for topical treatment of asthma. CSJ117 is a potent neutralizing antibody Fab fragment against TSLP, formulated as a PulmoSol TM engineered powder, and is delivered to the lungs by a dry powder inhaler. Phase 2 placebo-controlled clinical trial evaluated the efficacy and safety of CSJ117. CSJ117 delivered as an inhaler attenuated the late asthmatic response (LAR), and the early asthmatic response (EAR) after allergen inhalation challenge (AIC) at day 84 of treatment. The maximum decrease in FVE1 from pre-AIC were significantly lower in the CSJ117 group compared to placebo (P = 029), during LAR. CSJ117 also significantly reduced fractional exhaled nitric oxide before AIC at day 83; and significantly reduced the allergen-induced increase in % sputum eosinophil count. Pulmonary delivery of biologics directly to the airway mucosal surface has several advantages over parenteral routes, particularly in treating airway diseases such as asthma. Inhaler delivered biologics, such as CSJ117 are innovative and attractive methods of future precision treatment of asthma, and other respiratory diseases.

APA, Harvard, Vancouver, ISO, and other styles

3

Syabbalo, Nightingale. "Biologics in the Treatment of Severe Uncontrolled Asthma in Children." Journal of Thoracic Disease and Cardiothoracic Surgery 2, no. 2 (August 11, 2021): 01–08. http://dx.doi.org/10.31579/2693-2156/024.

Full text

Abstract:

Asthma is the most common chronic disease in children, currently affecting about 7 million children. Severe uncontrolled asthma is rare in children with a prevalence of about 2.1% to 5%, but inflicts a disproportionate health burden. Children with severe asthma have increased risk of life threatening exacerbations, frequent hospitalization, worsening health-related quality of life, and impaired physical activity. Severe asthma in childhood is associated with long-term morbidities, such as bronchiolitis obliterans, impaired airway development, and development of chronic obstructive pulmonary disease in adulthood. Childhood asthma like adult-onset asthma, is classified into four cellular inflammatory phenotypes using induced sputum cytometry. The four phenotypes of asthma include eosinophilic asthma, neutrophilic asthma, paucigranulocytic asthma, and mixed cellularity asthma. The pathophysiological mechanisms of asthma involve airway inflammation and remodeling. Inflammatory mediators such as cytokines, chemokines, adhesion molecules, and growth factors play a key role in orchestration airway remodeling. During airway inflammation, cytokines secreted by type 2 helper (Th2) lymphocytes, such as interleukin-5 (IL-5), IL-4, IL-13, IL-25, IL-33, and thymic stromal lymphopoietin (TSLP) play a key role in the pathogenesis of eosinophilic asthma. Whereas, the Th17 axis cytokines, including IL-17, IL-23, and IL-8 are responsible for the pathophysiology of neutrophilic asthma. The airway structural changes due to airway remodeling lead to thickening of the airway wall, narrowing of the bronchiolar lumen, airway obstruction, and decline in pulmonary function. Most of the children with asthma respond to low and medium inhaled corticosteroids, however a significant proportion still have severe asthma uncontrolled on the standard of care. The most common asthma phenotype in children is eosinophilic asthma, which responds superbly to biologic therapy. Children with severe asthma require add-on targeted interleukin antagonists (ILA), such as mepolizumab (anti-IL-5), benralizumab (anti-IL-5Rα), and dupilumab (anti-4Rα). ILAs have been shown to ameliorate asthma symptoms, reduce moderate and severe exacerbations, and improve pulmonary function. Additionally, ILAs have been demonstrated to improve the health-related quality of life, and have steroid sparing effect.

APA, Harvard, Vancouver, ISO, and other styles

4

Ivanova, N. A., E. I. Khubulava, N. A. Ivanova, and E. I. Hubulava. "Asthma treatment improvement." Russian Journal of Allergy 4, no. 3 (September 15, 2007): 58–62. http://dx.doi.org/10.36691/rja88.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Galant, Stanley P. "Treatment of asthma." Postgraduate Medicine 87, no. 4 (March 1990): 229–36. http://dx.doi.org/10.1080/00325481.1990.11704609.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

&NA;. "On asthma treatment." Inpharma Weekly &NA;, no. 740 (June 1990): 16. http://dx.doi.org/10.2165/00128413-199007400-00039.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Damani, S. "Individualizing Asthma Treatment." Science Translational Medicine 3, no. 104 (October 12, 2011): 104ec164. http://dx.doi.org/10.1126/scitranslmed.3003281.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Ward, MichaelJ. "TREATMENT OF ASTHMA." Lancet 327, no. 8480 (March 1986): 559. http://dx.doi.org/10.1016/s0140-6736(86)90913-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Bradley, David. "Dramatic asthma treatment." Pharmaceutical Science & Technology Today 1, no. 7 (October 1998): 289–90. http://dx.doi.org/10.1016/s1461-5347(98)00080-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Chung, K. F., and P. J. Barnes. "Treatment of asthma." BMJ 294, no. 6564 (January 10, 1987): 103–5. http://dx.doi.org/10.1136/bmj.294.6564.103.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Larenas Linnemann, Désirée E. S., Margarita Fernández Vega, Jorge Agustín Luna Pech, Jimena Villaverde Rosas, José Antonio Ortega Martell, Blanca Estela del Río Navarro, María del Carmen Cano Salas, et al. "Pediatric asthma treatment." Annals of Allergy, Asthma & Immunology 121, no. 1 (July 2018): 7–13. http://dx.doi.org/10.1016/j.anai.2018.03.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Alqalaf, Sayed Mahmood. "Asthma & COPD." Pharmaceutics and Pharmacology Research 5, no. 8 (September 30, 2022): 01–05. http://dx.doi.org/10.31579/2693-7247/092.

Full text

Abstract:

Asthma & COPD are the 2 major respiratory diseases that are widespread globally, though big differences between them exist in regard to their pathophysiology and treatment. The main treatment modalities for the two diseases are the inhalation routes of administration. The use of the inhalational routes of administration for the drugs used for the management of asthma and COPD is justified by many advantages such as the low effective dose, faster onset of action and lower systemic side effects. However, some advantages for these routes also exist. The major disadvantage is the technique of use, which many patients do not master even with repeated sessions of teaching by the healthcare providers. Difficulty in applying and following the correct inhalers use was found to be a major reason for patients’ non-adherence and consequently failure of the treatment plan.

APA, Harvard, Vancouver, ISO, and other styles

13

Rees, J., and J. Price. "ABC of Asthma: TREATMENT OF CHRONIC ASTHMA." BMJ 310, no. 6992 (June 3, 1995): 1459–63. http://dx.doi.org/10.1136/bmj.310.6992.1459.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Rees, J., and J. Price. "ABC of Asthma: ASTHMA IN CHILDREN: TREATMENT." BMJ 310, no. 6993 (June 10, 1995): 1522–27. http://dx.doi.org/10.1136/bmj.310.6993.1522.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Imanirad, Donya, and Farnaz Tabatabaian. "Current Biologics in Asthma Treatment." Seminars in Respiratory and Critical Care Medicine 43, no. 05 (October 2022): 627–34. http://dx.doi.org/10.1055/s-0042-1753486.

Full text

Abstract:

AbstractUncontrolled asthma and/or severe asthma causes significant impairments in quality of life and is often a huge health care burden. Monoclonal antibodies have been an important addition to the therapeutic management of patients with moderate to severe asthma who do not respond to conventional asthma management. Currently the majority of Food and Drug Administration (FDA) approved biologics target T2 high inflammation. However, with the expanding knowledge of asthma pathogenesis, novel therapeutics targeting T2 low inflammation are in development. In this article we will focus on the current understanding of T2 inflammation and approved biologics for moderate to severe asthma.

APA, Harvard, Vancouver, ISO, and other styles

16

Patel, Arshu P., and M. Siddaiah. "A brief review of some important medicinal plants used in the treatment of asthma." Journal of Drug Delivery and Therapeutics 8, no. 6-s (December 15, 2018): 347–49. http://dx.doi.org/10.22270/jddt.v8i6-s.2087.

Full text

Abstract:

Asthma is a common disease that is rising in prevalence worldwide with the highest prevalence in industrialized countries. Asthma affects about 300 million people worldwide and it has been estimated that a further 100 million will be affected by 2025. Ayurveda, Siddha, Unani and Folk (Tribal) medicines are the major systems of indigenous medicines. Over three-quarters of the world population relies mainly on plants and plant extracts for health care. Unlike many diseases, which can be attributed to the life style of modern man, asthma is an ancient illness. There are number of medicinal plants have been reported for antihistaminic/anti-asthmatic activities like Achyranthes aspera, Tephrosia purpurea, Dolichos lablab, Eclipta alba, Jasminum sambac, Balanites aegyptiaca, Viscum album, Tridex procumbens, Glycyrrhiza glabra and Cassia fistula. Present review is focused on used of medicinal plants for treatment of asthama. It is suggested that formulation and patent of the reported medicinal plants is mandatory for further use against asthma and if possible, clinical trials should be done of these plants for their appropriate use. Keywords: Medicinal plants, Asthma, Mast cells, Antihistaminic.

APA, Harvard, Vancouver, ISO, and other styles

17

Boulet, Louis-Philippe. "The Future of Asthma Treatment." Canadian Respiratory Journal 2, suppl a (1995): 46A—50A. http://dx.doi.org/10.1155/1995/674163.

Full text

Abstract:

In the past few years, significant progress has been made in the treatment of asthma with the development of bronchodilators with longer durations of action, more concentrated inhaled steroid formulations and new modes of administering antiasthma medication. Furthermore, the hey role of education in the management of asthma has been emphasized and many educational programs have been established. The recognition of the role of airway inflammation and structural changes in the physiopathology of asthma has led to a re-evaluation of asthma treatment guidelines. Anti-inflammatory drugs are now considered the mainstay of asthma therapy. An unprecedented number of new, potentially helpful agents have been developed and will soon be available. Among other expected developments are the identification and possible correction of genetic abnormalities responsible for the tendency to develop asthma and atopy, and prevention or functional and structural airway changes. This last goal will be achieved by improved environmental control, earlier use of more powerful and safe anti-inflammatory agents, as well as an increased involvement on the part of the asthma patient in treatment.

APA, Harvard, Vancouver, ISO, and other styles

18

Yang, Jing, Bo Song, and Junzi Wu. "Herbal Nanoformulations for Asthma Treatment." Current Pharmaceutical Design 28, no. 1 (January 2022): 46–57. http://dx.doi.org/10.2174/1381612827666210929113528.

Full text

Abstract:

Background: In recent decades, the prevalence of asthma has substantially increased worldwide. Advances in phytochemistry and phytopharmacology have clarified the active ingredients and biological activities of medicinal plant products for treating asthma, and the role of herbal therapies in asthma treatment has become increasingly evident. However, most plant extracts have low solubility and poor stability of bioactive components, resulting in low bioavailability and loss of efficacy. Owing to these shortcomings, the clinical use of many herbal extracts is limited. Objective: To summarise and analyse the characteristics of herbal nanoformulations and their application in asthma treatment. The objective of this review article is to address the emerging trends of herbal nanoformulations for an effective treatment of asthma. Methods: Various research and review articles from reputed international journals were referred to and compiled. Results: The nano-sized herbal formulations improve the solubility and bioavailability of herbal medicines and contribute to the sustained release of drugs, thus, increasing the therapeutic applications of herbal extracts. The review present different types of herbal nanoformulations, including micelles, nanoparticles, solid lipid nanoparticles, lipid-based liquid crystalline nanoparticles and nanoemulsions, which are potential nanodrugs for asthma treatment. Conclusions: Herbal nanoformulations have shown great prospects for the treatment of asthma in recent years. More safety and toxicity data are still needed to promote their development and application.

APA, Harvard, Vancouver, ISO, and other styles

19

van Aalderen, Wim M. "Childhood Asthma: Diagnosis and Treatment." Scientifica 2012 (2012): 1–18. http://dx.doi.org/10.6064/2012/674204.

Full text

Abstract:

Many children suffer from recurrent coughing, wheezing and chest tightness. In preschool children one third of all children have these symptoms before the age of six, but only 40% of these wheezing preschoolers will continue to have asthma. In older school-aged children the majority of the children have asthma. Quality of life is affected by asthma control. Sleep disruption and exercised induced airflow limitation have a negative impact on participation in sports and social activities, and may influence family life. The goal of asthma therapy is to achieve asthma control, but only a limited number of patients are able to reach total control. This may be due to an incorrect diagnosis, co-morbidities or poor inhalation technique, but in the majority of cases non-adherence is the main reason for therapy failures. However, partnership with the parents and the child is important in order to set individually chosen goals of therapy and may be of help to improve control. Non-pharmacological measures aim at avoiding tobacco smoke, and when a child is sensitised, to avoid allergens. In pharmacological management international guidelines such as the GINA guideline and the British Guideline on the Management of Asthma are leading.

APA, Harvard, Vancouver, ISO, and other styles

20

Coghlan, David, and Colin Powell. "Treatment of Childhood Asthma." Pediatric Drugs 5, no. 10 (2003): 685–98. http://dx.doi.org/10.2165/00148581-200305100-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Bratton, S. L. "Treatment for Severe Asthma." AAP Grand Rounds 7, no. 6 (June 1, 2002): 63. http://dx.doi.org/10.1542/gr.7-6-63.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

AKSU, Funda, and Kurtulus AKSU. "Individualized Treatment in Asthma." Güncel Göğüs Hastalıkları Serisi 8, no. 2 (September 15, 2020): 43–46. http://dx.doi.org/10.5152/gghs.2020.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Mira, Michael, and Suzanne Abraham. "The treatment of asthma." Medical Journal of Australia 143, no. 12-13 (December 1985): 633. http://dx.doi.org/10.5694/j.1326-5377.1985.tb119984.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Powell, Colin V. E., and Mark L. Everard. "Treatment of Childhood Asthma." Drugs 55, no. 2 (1998): 237–52. http://dx.doi.org/10.2165/00003495-199855020-00005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Choi, Byoung Whui. "Update in Asthma Treatment." Tuberculosis and Respiratory Diseases 61, no. 1 (2006): 5. http://dx.doi.org/10.4046/trd.2006.61.1.5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Betts, Anne V. "Asthma and its treatment." Nursing Standard 7, no. 8 (November 11, 1992): 9–14. http://dx.doi.org/10.7748/ns.7.8.9.s74.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Emelyanov, A. V., G. R. Sergeeva, O. V. Korovina, S. A. Sobchenko, and A. A. Znakhurenko. "MODERN TREATMENT OF ASTHMA." Russian Family Doctor 16, no. 2 (December 15, 2012): 9. http://dx.doi.org/10.17816/rfd201229-15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

TAL, ASHER, NISSIM LEVY, and Jacob E. Bearman. "Questioning Asthma Treatment Study." Pediatrics 88, no. 1 (July 1, 1991): 186. http://dx.doi.org/10.1542/peds.88.1.186.

Full text

Abstract:

In Reply.— We thank Drs McJunkin and Stallo for their interest in our paper. Their suggestion of using objective lung function measurements in young children and infants with acute asthma in the emergency department is impractical. The pulmonary index score we used includes at least one important lung function measure, namely, respiratory rate; this score also has been shown to be very reliable in children.1 Although we routinely use the peak expiratory flow rate in children in the emergency department, most of our patients were younger than 3 years of age and could not cooperate with this objective measurement.

APA, Harvard, Vancouver, ISO, and other styles

29

MCJUNKIN, JAMES E., and PAMELA S. STALLO. "Questioning Asthma Treatment Study." Pediatrics 88, no. 1 (July 1, 1991): 185–86. http://dx.doi.org/10.1542/peds.88.1.185a.

Full text

Abstract:

To the Editor.— The article "Methylprednisolone Therapy for Acute Asthma in Infants and Toddlers: A Controlled Clinical Trial" by Tal et al1 is interesting, but it does have some weak areas which perhaps the authors can address. First of all, the outcome which seems to be most emphasized in the study, ie, percent admitted, is a fairly weak outcome measure when compared with other more objective measures such as changes in pulmonary function. Note that the decision to discharge was made by the senior resident in charge of the emergency department.

APA, Harvard, Vancouver, ISO, and other styles

30

Choi, Inseon S. "Gender-Specific Asthma Treatment." Allergy, Asthma and Immunology Research 3, no. 2 (2011): 74. http://dx.doi.org/10.4168/aair.2011.3.2.74.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Smith, Elizabeth. "Guidelines for asthma treatment." Nursing Standard 9, no. 23 (March 1995): 3–15. http://dx.doi.org/10.7748/ns.9.23.3.s64.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Chipps, Bradley. "Treatment of Acute Asthma." Journal of Asthma 48, no. 7 (May 18, 2011): 751. http://dx.doi.org/10.3109/02770903.2011.580810.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Zacharisen, Michael C., and Jordan N. Fink. "Hyperthyroidism Complicating Asthma Treatment." Allergy and Asthma Proceedings 21, no. 2 (March 1, 2000): 71–74. http://dx.doi.org/10.2500/108854100778250950.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Kaplan, Mark, and Paul A. Greenberger. "Asthma: Principles of Treatment." Allergy and Asthma Proceedings 14, no. 2 (March 1, 1993): 121–22. http://dx.doi.org/10.2500/108854193778812189.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Millman, Richard P. "Treatment of Nocturnal Asthma." Allergy and Asthma Proceedings 14, no. 1 (January 2, 1993): 9–12. http://dx.doi.org/10.2500/108854193778816798.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

&NA;. "Advances in asthma treatment." Inpharma Weekly &NA;, no. 886 (May 1993): 16. http://dx.doi.org/10.2165/00128413-199308860-00041.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Ford, R. Munro, J. W. Paterson, and R. A. Tarala. "The treatment of asthma." Medical Journal of Australia 144, no. 12 (June 1986): 669. http://dx.doi.org/10.5694/j.1326-5377.1986.tb112362.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Czarny, Daniel. "The treatment of asthma." Medical Journal of Australia 145, no. 5 (September 1986): 241–42. http://dx.doi.org/10.5694/j.1326-5377.1986.tb113823.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Moura, José Augusto Rubim de, Jacques de Blic, and Paulo A. M. Camargos. "Prophylactic treatment of asthma." Jornal de Pediatria 78, no. 8 (November 15, 2002): 141–50. http://dx.doi.org/10.2223/jped.893.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Stillwell, P. "Chiropractic Treatment of Asthma." AAP Grand Rounds 1, no. 1 (January 1, 1999): 2–3. http://dx.doi.org/10.1542/gr.1-1-2-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Barry, P. W., and C. O'Callaghan. "Emergency treatment of asthma." Thorax 50, no. 7 (July 1, 1995): 814. http://dx.doi.org/10.1136/thx.50.7.814.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Lazarus, Stephen C. "Emergency Treatment of Asthma." New England Journal of Medicine 363, no. 8 (August 19, 2010): 755–64. http://dx.doi.org/10.1056/nejmcp1003469.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

SHAW, N. J., N. C. FRASER, and P. H. WELLER. "Asthma treatment and growth." Archives of Disease in Childhood 77, no. 4 (October 1, 1997): 284–86. http://dx.doi.org/10.1136/adc.77.4.284.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Rogers, Linda, and Joan Reibman. "Stepping down asthma treatment." Current Opinion in Pulmonary Medicine 18, no. 1 (January 2012): 70–75. http://dx.doi.org/10.1097/mcp.0b013e32834db017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Johansson, Gunnar, Björn Sta¨llberg, Göran Tornling, Stina Andersson, Göran S. Karlsson, Krister Fa¨lt, and Fredrik Berggren. "Asthma Treatment Preference Study." Chest 125, no. 3 (March 2004): 916–23. http://dx.doi.org/10.1378/chest.125.3.916.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Lehrer, Paul M., Evgeny Vaschillo, Bronya Vaschillo, Shou-En Lu, Anthony Scardella, Mahmood Siddique, and Robert H. Habib. "Biofeedback Treatment for Asthma." Chest 126, no. 2 (August 2004): 352–61. http://dx.doi.org/10.1378/chest.126.2.352.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Haahtela, T. "Early treatment of asthma." Allergy 54, s49 (March 1999): 74–81. http://dx.doi.org/10.1111/j.1398-9995.1999.tb04392.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Reiser, J., and J. O. Warner. "Inhalation treatment for asthma." Archives of Disease in Childhood 61, no. 1 (January 1, 1986): 88–94. http://dx.doi.org/10.1136/adc.61.1.88.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Ichinose, Masakazu. "Topics on asthma treatment." Nihon Naika Gakkai Zasshi 108, no. 6 (June 10, 2019): 1111–13. http://dx.doi.org/10.2169/naika.108.1111.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Osman, L., and S. Ross. "Treatment of childhood asthma." BMJ 311, no. 6999 (July 22, 1995): 260. http://dx.doi.org/10.1136/bmj.311.6999.260a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!